CHRS
Price:
$1.4
Market Cap:
$171.37M
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, m...[Read more]
Industry
Biotechnology
IPO Date
2014-11-06
Stock Exchange
NASDAQ
Ticker
CHRS
According to Coherus Oncology, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 110.51M. This represents a change of 34.35% compared to the average of 82.25M of the last 4 quarters.
The mean historical Enterprise Value of Coherus Oncology, Inc. over the last ten years is 795.26M. The current 110.51M Enterprise Value has changed 1.29% with respect to the historical average. Over the past ten years (40 quarters), CHRS's Enterprise Value was at its highest in in the June 2019 quarter at 1.64B. The Enterprise Value was at its lowest in in the June 2025 quarter at -90976370.68.
Average
795.26M
Median
861.61M
Minimum
122.38M
Maximum
1.27B
Discovering the peaks and valleys of Coherus Oncology, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 104.42%
Maximum Annual Enterprise Value = 1.27B
Minimum Annual Increase = -61.73%
Minimum Annual Enterprise Value = 122.38M
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 122.38M | -59.48% |
| 2024 | 302.00M | -56.33% |
| 2023 | 691.51M | -32.97% |
| 2022 | 1.03B | -14.45% |
| 2021 | 1.21B | 7.96% |
| 2020 | 1.12B | -11.73% |
| 2019 | 1.27B | 104.42% |
| 2018 | 619.10M | 40.04% |
| 2017 | 442.07M | -61.73% |
| 2016 | 1.16B | 66.42% |
The current Enterprise Value of Coherus Oncology, Inc. (CHRS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
371.97M
5-year avg
670.72M
10-year avg
795.26M
Coherus Oncology, Inc.’s Enterprise Value is less than OmniAb, Inc. (260.96M), greater than Invivyd, Inc. (-73325330.00), less than SELLAS Life Sciences Group, Inc. (1.01B), less than Codexis, Inc. (254.06M), less than Avalo Therapeutics, Inc. (144.04M), less than Protalix BioTherapeutics, Inc. (135.16M), less than C4 Therapeutics, Inc. (320.20M), less than Insight Molecular Diagnostics Inc. (125.45M), greater than Sangamo Therapeutics, Inc. (53.89M), less than Protara Therapeutics, Inc. (138.82M),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 260.96M | $270.34M | |
| -73325330.00 | $102.20M | |
| 1.01B | $1.12B | |
| 254.06M | $218.15M | |
| 144.04M | $166.70M | |
| 135.16M | $168.39M | |
| 320.20M | $323.03M | |
| 125.45M | $150.58M | |
| 53.89M | $62.14M | |
| 138.82M | $150.50M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Coherus Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Coherus Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Coherus Oncology, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Coherus Oncology, Inc. (CHRS)?
What is the 3-year average Enterprise Value for Coherus Oncology, Inc. (CHRS)?
What is the 5-year average Enterprise Value for Coherus Oncology, Inc. (CHRS)?
How does the current Enterprise Value for Coherus Oncology, Inc. (CHRS) compare to its historical average?